Safety and tolerability of glucagon-like peptide-1 receptor agonists: unresolved and emerging issues

References

• Elrick H, Stimmler L, Hlad C, et al. Plasma insulin response to oral and intravenous glucose asministration. J Clin Endocrinol Metab. 1964;24:1076–1082.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol. 2016;4:525–536.
   PubMed Web of Science ®Google Scholar
• Freeman JS. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus. Cleve Clin J Med. 2009;76(Suppl 5):S12–S19.
   PubMedGoogle Scholar
• Hui H, Farilla L, Merkel P, et al. The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects. Eur J Endocrinol. 2002;146:863–869.
   PubMed Web of Science ®Google Scholar
• Uccellatore A, Genovese S, Dicembrini I, et al. Comparison review of short-acting and long-acting glucagon-like peptide-1 receptor agonists. Diabetes Ther. 2015;6:239–256.
   PubMed Web of Science ®Google Scholar
• Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett. 1995;358:219–224.
   PubMed Web of Science ®Google Scholar
• Davidson MB, Bate G, Kirkpatrick P. Exenatide. Nat Rev Drug Discov. 2005;4:713–714.
   PubMed Web of Science ®Google Scholar
• Minor RK, Chang JW, de Cabo R. Hungry for life: how the arcuate nucleus and neuropeptide Y may play a critical role in mediating the benefits of calorie restriction. Mol Cell Endocrinol. 2009;299:79–88.
   PubMed Web of Science ®Google Scholar
• Madsbad S. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab. 2016;18:317–332.
   PubMed Web of Science ®Google Scholar
• Zaccardi F, Htike ZZ, Webb DR, et al. Benefits and harms of once-weekly glucagon-like peptide-1 receptor agonist treatments: a systematic review and network meta-analysis. Ann Intern Med. 2016;164:102–113.
   PubMed Web of Science ®Google Scholar
• Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8:728–742.
   PubMed Web of Science ®Google Scholar
• Anderson SL, Trujillo JM. Lixisenatide in type 2 diabetes: latest evidence and clinical usefulness. Ther Adv Chronic Dis. 2016;7:4–17.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–1844.
   PubMed Web of Science ®Google Scholar
• Ahrén B, Leguizamo DA, Miossec P, et al. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care. 2013;36:2543–2550.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Raccah D, Koranyi L, et al. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care. 2013;36:2945–2951.
   PubMed Web of Science ®Google Scholar
• Esposito K, Mosca C, Brancario C, et al. GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Curr Med Res Opin. 2011;27:1519–1528.
   PubMed Web of Science ®Google Scholar
• Diamant M, Nauck MA, Shaginian R, et al. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diabetes Care. 2014;37:2763–2773.
   PubMed Web of Science ®Google Scholar
• Eng C, Kramer CK, Zinman B, et al. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet. 2014;384:2228–2234.
   PubMed Web of Science ®Google Scholar
• Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2015;6:19–28.
   PubMed Web of Science ®Google Scholar
• Liu FP, Dong JJ, Yang Q, et al. Glucagon-like peptide 1 receptor agonist therapy is more efficacious than insulin glargine for poorly controlled type 2 diabetes: a systematic review and meta-analysis. J Diabetes. 2015;7:322–328.
   PubMed Web of Science ®Google Scholar
• Karagiannis T, LIakos A, Bekiari E, et al. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2015;17:1065–1074.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American diabetes association and the European association for the study of diabetes. Diabetologia. 2015;58:429–442.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Lyxumia: summary of product characteristics. [cited 2016 Jun 10]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002445/WC500140401.pdf
   Google Scholar
• European Medicines Agency. Byetta: summary of product characteristics. [cited 2016 Jun 10]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000698/WC500051845.pdf
   Google Scholar
• European Medicines Agency, Eu. Bydureon: summary of product characteristics. [cited 2016 Jun 10]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002020/WC500108241.pdf
   Google Scholar
• European Medicines Agency. Victoza: summary of product characteristics. [cited 2016 Jun 10]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001026/WC500050017.pdf
   Google Scholar
• European Medicines Agency. Trulicity: summary of product characteristics. [cited 2016 Jun 10]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002825/WC500179470.pdf
   Google Scholar
• European Medicines Agency. Eperzan: summary of product characteristics.[cited 2016 Jun 10]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002735/WC500165117.pdf
   Google Scholar
• Advani A, Bugyei-Twum A, Connelly KA. Cardiovascular effects of incretins in diabetes. Can J Diabetes. 2013;37:309–314.
   PubMed Web of Science ®Google Scholar
• Kapitza C, Forst T, Coester HV, et al. Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. Diabetes Obes Metab. 2013;15:642–649.
   PubMed Web of Science ®Google Scholar
• Gill A, Hoogwerf BJ, Burger J, et al. Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol. 2010;9:6.
   PubMed Web of Science ®Google Scholar
• Meier JJ, Rosenstock J, Hincelin-Mery A, et al. Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial. Diabetes Care. 2015;38:1263–1273.
   PubMed Web of Science ®Google Scholar
• Lorenz M, Owens D, Raccah D, et al. Differential effects of GLP-1 receptor agonists on 24-hour average heart rate in healthy volunteers and patients with type 2 diabetes. Diabetologia. 2015;58(Suppl 1):OP 03–16.
   Google Scholar
• Sun F, Wu S, Guo S, et al. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Res Clin Pract. 2015;110:26–37.
   PubMed Web of Science ®Google Scholar
• ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319–328.
   PubMed Web of Science ®Google Scholar
• Monami M, Dicembrini I, Nardini C, et al. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16:38–47.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–2257.
   PubMed Web of Science ®Google Scholar
• Patorno E, Everett BM, Goldfine AB, et al. Comparative cardiovascular safety of glucagon-like peptide-1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study. Diabetes Obes Metab. 2016;18:755–765.
   PubMed Web of Science ®Google Scholar
• Stratton IM, Cull CA, Adler AI, et al. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia. 2006;49:1761–1769.
   PubMed Web of Science ®Google Scholar
• Smits MM, Muskiet MH, Tonneijck L, et al. Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males. Br J Clin Pharmacol. 2016;81:613–620.
   PubMed Web of Science ®Google Scholar
• Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res. 2014;114:1788–1803.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322.
   PubMed Web of Science ®Google Scholar
• Balena R, Hensley IE, Miller S, et al. Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes Obes Metab. 2013;15:485–502.
   PubMed Web of Science ®Google Scholar
• Riddle MC, Aronson R, Home P, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care. 2013;36:2489–2496.
   PubMed Web of Science ®Google Scholar
• Riddle MC, Forst T, Aronson R, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Diabetes Care. 2013;36:2497–2503.
   PubMed Web of Science ®Google Scholar
• Seino Y, Min KW, Niemoeller E, et al. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab. 2012;14:910–917.
   PubMed Web of Science ®Google Scholar
• de Wit HM, Te Groen M, Rovers MM, et al. The placebo response of injectable GLP-1 receptor agonists versus oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;82:301–314.
   PubMed Web of Science ®Google Scholar
• Gough SC, Bode B, Woo V, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2:885–893.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Arranz C, Grunberger G, et al. Benefits of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: the LixiLan-O randomized trial. Diabetes Care. 2016;39:2026–2035.
   PubMed Web of Science ®Google Scholar
• Pratley RE, Nauck MA, Barnett AH, et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol. 2014;2:289–297.
   PubMed Web of Science ®Google Scholar
• Raccah D, Miossec P, Esposito V, et al. Efficacy and safety of lixisenatide in elderly (>65 years) and very elderly (>75 years) patients with type 2 diabetes: an analysis from the phase 3 GetGoal program. Diabetes Metab Res Rev. 2015;31:204–211.
   PubMed Web of Science ®Google Scholar
• Kirkman MS, Briscoe VJ, Clark N, et al. Diabetes in older adults: a consensus report. J Am Geriatr Soc. 2012;60:2342–2356.
   PubMed Web of Science ®Google Scholar
• Abdelhafiz AH, Rodriguez-Manas L, Morley JE, et al. Hypoglycemia in older people - a less well recognized risk factor for frailty. Aging Dis. 2015;6:156–167.
   PubMed Web of Science ®Google Scholar
• Meneilly G, Alawi H, Dailey G, et al. Lixisenatide therapy in older patients with Type 2 diabetes inadequately controlled on their current antidiabetic treatment: the GetGoal-O study (NCT01798706). Diabet Med. 2016;33(Suppl 1):146 (P375).
   Google Scholar
• Kos K, McCulloch L, Ward R, et al. Adipose tissue response to GLP-1 analogue-induced weight loss. Diabetologia. 2015;58(Suppl 1):OP 03–14.
   Google Scholar